Pharmacogenetic Tests for Antipsychotic-Induced Weight Gain

E. O. Zhuravleva; N. Yu. Vel’ts; I. I. Snegireva; G. V. Kutekhova; R. N. Alyautdin

doi:10.1007/s11094-019-02059-z

Pharmacogenetic Tests for Antipsychotic-Induced Weight Gain

Autores: Zhuravleva E.O.¹, Vel’ts N.Y.¹, Snegireva I.I.¹, Kutekhova G.V.¹, Alyautdin R.N.¹
Afiliações:
1. Ministry of Health of the Russian Federation, Scientific Center for Expert Evaluation of Medicinal Products
Edição: Volume 53, Nº 7 (2019)
Páginas: 668-671
Seção: Discussion
URL: https://journals.rcsi.science/0091-150X/article/view/245937
DOI: https://doi.org/10.1007/s11094-019-02059-z
ID: 245937

Citar

Texto integral

Acesso aberto
Acesso é fechado

Acesso está concedido
Acesso é fechado

Somente assinantes

Resumo
Sobre autores
Bibliografia
Arquivos suplementares
Estatísticas

Resumo

Second-generation antipsychotic substances, as compared with first-generation antipsychotics, are more effective in relation to psychotic symptoms and have significantly lower potential for developing extrapyramidal impairments such as parkinsonism and late dyskinesia. However, use of these agents is associated with significant weight gain in patients. Advances in the pharmacogenetics of antipsychotic-induced weight gain are analyzed here.